These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma. Zhang X; Wang X; Xu T; Zhong S; Shen Z Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752 [TBL] [Abstract][Full Text] [Related]
23. Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia. Fang Y; Yang Y; Hua C; Xu S; Zhou M; Guo H; Wang N; Zhao X; Huang L; Yu F; Cheng H; Wang ML; Meng L; Cheng T; Yuan W; Ma D; Zhou J Leukemia; 2017 Feb; 31(2):414-422. PubMed ID: 27499138 [TBL] [Abstract][Full Text] [Related]
24. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Yoshimi A; Goyama S; Watanabe-Okochi N; Yoshiki Y; Nannya Y; Nitta E; Arai S; Sato T; Shimabe M; Nakagawa M; Imai Y; Kitamura T; Kurokawa M Blood; 2011 Mar; 117(13):3617-28. PubMed ID: 21289308 [TBL] [Abstract][Full Text] [Related]
26. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247 [TBL] [Abstract][Full Text] [Related]
27. Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia. Ghosh J; Kapur R Exp Hematol; 2017 Jun; 50():13-21. PubMed ID: 28342808 [TBL] [Abstract][Full Text] [Related]
28. Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells. Rosario FJ; Kanai Y; Powell TL; Jansson T J Physiol; 2013 Feb; 591(3):609-25. PubMed ID: 23165769 [TBL] [Abstract][Full Text] [Related]
29. Mammalian target of rapamycin complex 1 signalling is essential for germinal centre reaction. Li B; Li Z; Wang P; Huang Q; Xu L; He R; Ye L; Bai Q Immunology; 2017 Oct; 152(2):276-286. PubMed ID: 28557002 [TBL] [Abstract][Full Text] [Related]
30. Identification of rictor as a novel substrate of Polo-like kinase 1. Shao T; Liu X Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006 [TBL] [Abstract][Full Text] [Related]
31. mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Lee JY; Nakada D; Yilmaz OH; Tothova Z; Joseph NM; Lim MS; Gilliland DG; Morrison SJ Cell Stem Cell; 2010 Nov; 7(5):593-605. PubMed ID: 21040901 [TBL] [Abstract][Full Text] [Related]
32. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts. Shu L; Houghton PJ Mol Cell Biol; 2009 Sep; 29(17):4691-700. PubMed ID: 19564418 [TBL] [Abstract][Full Text] [Related]
33. Cutting edge: Discrete functions of mTOR signaling in invariant NKT cell development and NKT17 fate decision. Wei J; Yang K; Chi H J Immunol; 2014 Nov; 193(9):4297-4301. PubMed ID: 25261481 [TBL] [Abstract][Full Text] [Related]
34. Distribution and association of mTOR with its cofactors, raptor and rictor, in cumulus cells and oocytes during meiotic maturation in mice. Kogasaka Y; Hoshino Y; Hiradate Y; Tanemura K; Sato E Mol Reprod Dev; 2013 Apr; 80(4):334-48. PubMed ID: 23440873 [TBL] [Abstract][Full Text] [Related]
35. Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. Foster KG; Acosta-Jaquez HA; Romeo Y; Ekim B; Soliman GA; Carriere A; Roux PP; Ballif BA; Fingar DC J Biol Chem; 2010 Jan; 285(1):80-94. PubMed ID: 19864431 [TBL] [Abstract][Full Text] [Related]
36. The Akt-mTOR network at the interface of hematopoietic stem cell homeostasis. Wu F; Chen Z; Liu J; Hou Y Exp Hematol; 2021 Nov; 103():15-23. PubMed ID: 34464661 [TBL] [Abstract][Full Text] [Related]
37. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922 [TBL] [Abstract][Full Text] [Related]
38. mTORC2 is required for proliferation and survival of TSC2-null cells. Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669 [TBL] [Abstract][Full Text] [Related]
39. PTEN in the haematopoietic system and its therapeutic indications. Cheung AM; Mak TW Trends Mol Med; 2006 Nov; 12(11):503-5. PubMed ID: 16996801 [TBL] [Abstract][Full Text] [Related]
40. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]